Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) traded ~10% higher on Tuesday after the Pennsylvania-based biotech posted a strong ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal Pharmaceuticals inks $2.1 billion deal with Chinese firm for MASH treatment, aiming to enhance Rezdiffra's efficacy ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

Learn insights from Madrigal Pharmaceuticals' Q2 2025 earnings: Rezdiffra's growth, new patent till 2045, global expansion, and pipeline advances.

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.